![Thomas E. Willnow](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas E. Willnow
Corporate Officer/Principal chez
Humboldt-Universität zu Berlin
Profil
Thomas E.
Willnow was the founder of Recepticon ApS, which was founded in 2001, where he held the title of Director & Co-Chief Scientific Officer from 2009 to 2010.
He currently holds the title of Principal at Humboldt-Universität zu Berlin.
Dr. Willnow has held the title of Principal at AGC Biologics SpA and Roche Diagnostics GmbH in the past.
Dr. Willnow received a doctorate degree from Ludwig-Maximilians-Universität München in 1992 and an undergraduate degree from the same institution.
Postes actifs de Thomas E. Willnow
| Sociétés | Poste | Début |
|---|---|---|
Humboldt-Universität zu Berlin
 Humboldt-Universität zu Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 02/09/2009 |
Anciens postes connus de Thomas E. Willnow
| Sociétés | Poste | Fin |
|---|---|---|
Recepticon ApS
 Recepticon ApS Pharmaceuticals: MajorHealth Technology Develops receptor antagonists for prevention of medical induced organ damage | Fondateur | 23/03/2010 |
| MOLMED S.P.A. | Corporate Officer/Principal | - |
Roche Diagnostics GmbH
 Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Develops innovative medicines, treatments and diagnostics | Corporate Officer/Principal | - |
Formation de Thomas E. Willnow
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
63
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
AGC Biologics SpA
 AGC Biologics SpA Pharmaceuticals: MajorHealth Technology Provides pharmaceutical development and manufacturing services for protein-based biologics, cells & gene therapies and messenger RNA | Health Technology |
Roche Diagnostics GmbH
Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Develops innovative medicines, treatments and diagnostics | Commercial Services |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Recepticon ApS
Recepticon ApS Pharmaceuticals: MajorHealth Technology Develops receptor antagonists for prevention of medical induced organ damage | Health Technology |
Humboldt-Universität zu Berlin
Humboldt-Universität zu Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Choisissez Zonebourse 
